Several other brokerages have also recently weighed in on VERU. Maxim Group initiated coverage on Veru in a report on Tuesday, July 3rd. They set a buy rating for the company. Zacks Investment Research cut Veru from a hold rating to a sell rating in a report on Tuesday, August 21st. Dawson James reissued a buy rating on shares of Veru in a report on Monday, June 25th. Finally, ValuEngine raised Veru from a hold rating to a buy rating in a report on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $5.83.
Shares of NASDAQ:VERU opened at $1.78 on Thursday. Veru has a 1-year low of $0.90 and a 1-year high of $3.00. The company has a current ratio of 1.01, a quick ratio of 0.80 and a debt-to-equity ratio of 0.12.
An institutional investor recently bought a new position in Veru stock. ACG Wealth purchased a new stake in Veru Inc (NASDAQ:VERU) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 77,000 shares of the company’s stock, valued at approximately $156,000. ACG Wealth owned about 0.14% of Veru at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.20% of the company’s stock.
Veru Company Profile
Veru Inc operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Featured Article: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.